Simcere Pharmaceutical Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609

Reuters

2025/09/08

<a href="https://laohu8.com/S/SMHGF">Simcere Pharmaceutical</a> Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609

Simcere Pharmaceutical Group Ltd. has announced the approval of a clinical trial for its anti-tumor drug candidate, SIM0609, by the National Medical Products Administration of China. SIM0609 is a CDH17 Antibody-Drug Conjugate $(ADC)$, developed by Simcere, designed to target advanced solid tumors. The drug consists of a humanized monoclonal antibody linked to the company's proprietary topoisomerase I inhibitor through a novel hydrophilic cleavable linker. CDH17, highly expressed in various cancers such as gastric, colorectal, and pancreatic cancers, is identified as a promising therapeutic target for the treatment of advanced solid tumors, particularly gastrointestinal carcinomas. The results of the clinical trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief on September 08, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2565689544"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565689544\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565689544?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565689544","market":"nz","top_or_hot":-1,"title":"Simcere Pharmaceutical Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SMHGF\">Simcere Pharmaceutical</a> Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Simcere Pharmaceutical Group Ltd. has announced the approval of a clinical trial for its anti-tumor drug candidate, SIM0609, by the National Medical Products Administration of China. SIM0609 is a CDH17 Antibody-Drug Conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, developed by Simcere, designed to target advanced solid tumors. The drug consists of a humanized monoclonal antibody linked to the company's proprietary topoisomerase I inhibitor through a novel hydrophilic cleavable linker. CDH17, highly expressed in various cancers such as gastric, colorectal, and pancreatic cancers, is identified as a promising therapeutic target for the treatment of advanced solid tumors, particularly gastrointestinal carcinomas. The results of the clinical trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simcere Pharmaceutical Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimcere Pharmaceutical Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-08 20:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SMHGF\">Simcere Pharmaceutical</a> Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Simcere Pharmaceutical Group Ltd. has announced the approval of a clinical trial for its anti-tumor drug candidate, SIM0609, by the National Medical Products Administration of China. SIM0609 is a CDH17 Antibody-Drug Conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, developed by Simcere, designed to target advanced solid tumors. The drug consists of a humanized monoclonal antibody linked to the company's proprietary topoisomerase I inhibitor through a novel hydrophilic cleavable linker. CDH17, highly expressed in various cancers such as gastric, colorectal, and pancreatic cancers, is identified as a promising therapeutic target for the treatment of advanced solid tumors, particularly gastrointestinal carcinomas. The results of the clinical trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先聲藥業","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL1KrB58:1","article_id":"2565689544","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565689544","pubTimestamp":1757333501,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Simcere Pharmaceutical Group Ltd. has announced the approval of a clinical trial for its anti-tumor drug candidate, SIM0609, by the National Medical Products Administration of China. SIM0609 is a CDH17 Antibody-Drug Conjugate , developed by Simcere, designed to target advanced solid tumors. The drug consists of a humanized monoclonal antibody linked to the company's proprietary topoisomerase I inhibitor through a novel hydrophilic cleavable linker. CDH17, highly expressed in various cancers such as gastric, colorectal, and pancreatic cancers, is identified as a promising therapeutic target for the treatment of advanced solid tumors, particularly gastrointestinal carcinomas. The results of the clinical trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业","BK1583":"高瓴概念","BK1191":"制药"},"translate_title":"先声药业集团宣布抗肿瘤创新药SIM0609获批临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":0.9},"content_text":"Simcere Pharmaceutical Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609\n    \n\n        Simcere Pharmaceutical Group Ltd. has announced the approval of a clinical trial for its anti-tumor drug candidate, SIM0609, by the National Medical Products Administration of China. SIM0609 is a CDH17 Antibody-Drug Conjugate $(ADC)$, developed by Simcere, designed to target advanced solid tumors. The drug consists of a humanized monoclonal antibody linked to the company's proprietary topoisomerase I inhibitor through a novel hydrophilic cleavable linker. CDH17, highly expressed in various cancers such as gastric, colorectal, and pancreatic cancers, is identified as a promising therapeutic target for the treatment of advanced solid tumors, particularly gastrointestinal carcinomas. The results of the clinical trial have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief on September 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}